CLINICAL_TRIALS
ClinicalTrials.gov record update
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01885897
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:36.917243+00:00
- Published At
- 2020-08-12T00:00:00+00:00
- Record Updated At
- 2020-08-12
- Results Posted At
- 2020-08-12
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Acute Myelogenous Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndromes (MDS)", "Lymphoma", "Myeloma", "Chronic Lymphocytic Leukemia (CLL)", "Chronic Myelogenous Leukemia (CML)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-08-12"- protocolSection.identificationModule.nctId
"NCT01885897"- protocolSection.identificationModule.officialTitle
"IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-08-12"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.